Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharmather Hldgs Ltd (OP: PHRRF ) 0.1670 -0.0028 (-1.65%) Streaming Delayed Price Updated: 3:32 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 35,170 Open 0.1670 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.1698 Today's Range 0.1650 - 0.1710 52wk Range 0.0822 - 0.3200 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine May 15, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine May 10, 2024 The FDA Assigned Goal Date is October 29, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire Performance YTD -32.39% -32.39% 1 Month +13.22% +13.22% 3 Month -6.65% -6.65% 6 Month -7.22% -7.22% 1 Year +55.93% +55.93% More News Read More PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine May 01, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine April 18, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine April 16, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder April 02, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia February 21, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine February 12, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More January 15, 2024 Via Benzinga PharmaTher Provides Update for Expected FDA Approval of Ketamine January 10, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Via Benzinga PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance September 27, 2023 Via Benzinga Exposures Product Safety PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine) September 27, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years September 12, 2023 Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application September 06, 2023 Via Benzinga Exposures Product Safety PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA September 06, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More July 24, 2023 Via Benzinga PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage July 18, 2023 Via Benzinga PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics July 18, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 Via Benzinga BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives June 28, 2023 Via Benzinga Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets June 27, 2023 Via Benzinga PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA June 27, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement June 20, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
